Literature DB >> 31650292

Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.

Ali Alkan1, Özgür Tanrıverdi2.   

Abstract

Entities:  

Year:  2019        PMID： 31650292     DOI： 10.1007/s00520-019-05105-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

1.  Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.

Authors:  Signe Harder; Mogens Groenvold; Jesper Isaksen; Jarl Sigaard; Karin Bruun Frandsen; Mette Asbjoern Neergaard; Lise Mondrup; Jørn Herrstedt
Journal:  Support Care Cancer       Date:  2018-12-14       Impact factor: 3.603

Review 2.  Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.

Authors:  Ting Yang; Qianxin Liu; Min Lu; Lingyue Ma; Ying Zhou; Yimin Cui
Journal:  Br J Clin Pharmacol       Date:  2017-03-23       Impact factor: 4.335

3.  Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.

Authors:  Manish Srivastava; Norman Brito-Dellan; Mellar P Davis; Marie Leach; Ruth Lagman
Journal:  J Pain Symptom Manage       Date:  2003-06       Impact factor: 3.612

4.  Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients.

Authors:  Ali Alkan; Arzu Yaşar; Ebru Karcı; Elif Berna Köksoy; Muslih Ürün; Filiz Çay Şenler; Yüksel Ürün; Gülseren Tuncay; Hakan Ergün; Hakan Akbulut
Journal:  Support Care Cancer       Date:  2016-09-12       Impact factor: 3.603

5.  Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol.

Authors:  Mona Gupta; Mellar Davis; Susan LeGrand; Declan Walsh; Ruth Lagman
Journal:  J Support Oncol       Date:  2013-03
  5 in total
  1 in total

1.  Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.

Authors:  Signe Harder; Mogens Groenvold; Jørn Herrstedt
Journal:  Support Care Cancer       Date:  2020-01-10       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.